Fig. 3From: Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapyInvasive disease-free survival (IDFS) according to clinical stage (a), achieving pCR (b), pSUVmax (c), SUVmax of axilla (d), expressions of estrogen receptor (ER, e), progesterone receptor (PR, f) and Ki67 index (g), and molecular subtype (h)Back to article page